Trending...
- Composer Andrew Prahlow to Perform Award-Winning Outer Wilds Soundtrack on Oct 17th at Brooklyn's Music Hall of Williamsburg
- Delta Industrial is Attending FabTech 2024 in Orlando This Fall
- VSA Officially Receives SOC 2 Approval
IGC Pharma, Inc. (NYSE American: IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database.
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
POTOMAC, Md. - Michimich -- IGC Pharma, Inc. (NYSE American: IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database.
The PREPARE Challenge, is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institute of Health ("NIH"). The competition aims to accelerate the development of more accurate, innovative, and representative tools for Alzheimer's and related dementias. The Disproportionate Impact prize recognizes the submission with the most potential to support algorithms that generalize to populations disproportionately impacted by AD/ADRD.
IGC's entry in Phase 1 of the PREPARE Challenge won 3rd prize overall and the Disproportionate Impact prize. "We are honored to win the two PREPARE prizes. These recognitions underscore IGC's leadership in artificial intelligence ("AI") and deep learning research aimed at improving Alzheimer's disease prediction," commented CEO Ram Mukunda.
There are approximately 400 million individuals in the preclinical stage of Alzheimer's exhibiting early brain changes, such as plaque buildup, that could lead to cognitive decline within 20 years. By harnessing deep learning models, IGC is developing scalable and cost-effective diagnostic predictors that bypass expensive imaging techniques and ultimately predict cognitive decline two decades before symptoms manifest.
More on Michimich.com
Early prediction improves patient outcomes and can help significantly reduce caregiving and healthcare costs.
Ram Mukunda continued, "We believe our early prediction AI initiatives can offer significant hope to patients and caregivers, create long time value for shareholders, and alleviate the projected $1 trillion economic burden on the U.S. healthcare system from Alzheimer's disease."
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
More on Michimich.com
Forward-looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contacts
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
The PREPARE Challenge, is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institute of Health ("NIH"). The competition aims to accelerate the development of more accurate, innovative, and representative tools for Alzheimer's and related dementias. The Disproportionate Impact prize recognizes the submission with the most potential to support algorithms that generalize to populations disproportionately impacted by AD/ADRD.
IGC's entry in Phase 1 of the PREPARE Challenge won 3rd prize overall and the Disproportionate Impact prize. "We are honored to win the two PREPARE prizes. These recognitions underscore IGC's leadership in artificial intelligence ("AI") and deep learning research aimed at improving Alzheimer's disease prediction," commented CEO Ram Mukunda.
There are approximately 400 million individuals in the preclinical stage of Alzheimer's exhibiting early brain changes, such as plaque buildup, that could lead to cognitive decline within 20 years. By harnessing deep learning models, IGC is developing scalable and cost-effective diagnostic predictors that bypass expensive imaging techniques and ultimately predict cognitive decline two decades before symptoms manifest.
More on Michimich.com
- Hillside Terrace Senior Living Encourages Supporting Your Loved Ones' Emotional Well-Being
- The Giant is Coming to Las Vegas: A Landmark Blending Art, Entertainment & Blockchain for an Unforgettable Experience!
- Nurturing Healthy Smiles Through Little Mouth Program
- Experience the Future of Digital Textbook with KITABOO at FBF 2024 and Win an iPad Daily!
- Integris Composites Displays New Military Armor at AUSA 2024
Early prediction improves patient outcomes and can help significantly reduce caregiving and healthcare costs.
Ram Mukunda continued, "We believe our early prediction AI initiatives can offer significant hope to patients and caregivers, create long time value for shareholders, and alleviate the projected $1 trillion economic burden on the U.S. healthcare system from Alzheimer's disease."
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
More on Michimich.com
- Expert HVAC Upgrade Tips to Maximize Energy Efficiency
- ALLTRA SonicSwap Expands DeFi Opportunities with Weekly Listings and Global Partnerships
- ALL Mainnet Launches AUSDT Stablecoin onto the global arena
- The Giving Edge: Is Leveraging Outrageous Kindness the Missing Link for Corporate ROI?
- One Of The Largest Native American Burial Sites In The United States Moves A Step Closer To National Recognition
Forward-looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contacts
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
Contact
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
IMS Investor Relations
Rosalyn Christian / Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
Source: IGC PHARMA
Filed Under: Health
0 Comments
Latest on Michimich.com
- Restoration Specialists Celebrates a Successful 2024 and Strong Q4
- Purple Union C-Murder Supporting Angola Prisoners in Their Fight for Basic Human Rights Through Labor Strike
- OpsVeda Is Now Available Through AWS Marketplace
- Circumference Group Acquires Majority Stake in Visionary Integration Professionals
- C & C Heating & Air Conditioning says the way to combat high energy costs is with a heating tune-up
- Tim O'Loughlin Appointed Chief Executive Officer of Vantiva and Co-opted as a Director of the Board
- TN Nursery Gears Up for Busy Fall Shipping Season with Nationwide Fast Shipping, Low Grower Prices, and Storewide Deals
- Jazz Artist Bob Holz Signs With SoVibe Entertainment Plus Album Review In September 2024 Issue Of Downbeat Magazine
- Develop Africa Partners with Sierra Leonean Painter Sahr Songu Mbriwa to Raise Funds for Education
- Composer Andrew Prahlow to Perform Award-Winning Outer Wilds Soundtrack on Oct 17th at Brooklyn's Music Hall of Williamsburg
- Plastic Fabrication Company Shares Benefits of Medical Device Plastics
- Cell-Ed and National Minority Health Association Forge Strategic Partnership to Expand Caregiving and Health Equity Initiatives
- Delta Industrial is Attending FabTech 2024 in Orlando This Fall
- Fortius Metals secures $2 Million Additional Funding to Bring Advanced Metal 3D Printing to the Aerospace and Defense Industry
- Michigan SEO Group Shares Local Marketing Strategies for Your Social Media in Ann Arbor, MI
- Voices Rising Festival Celebrates Diversity in E. Islip, GRAMMY Governor LACHI performs!
- VSA Officially Receives SOC 2 Approval
- ELKEM TO SHOWCASE ITS THERMAL MANAGEMENT MATERIALS AT THE BATTERY SHOW
- Martial Arts Icon Cynthia Rothrock Premieres Her Latest Film Black Creek
- Vantiva and Harmonic Partner to Offer Service Providers Easy Transition from DOCSIS to Fiber-based PON Technologies